Dana-Farber Cancer Institute

Four things payers need to know about acute myeloid leukemiaPhysicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
FDA approves first immunostimulatory antibody for multiple myelomaAn oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.
Waldenstrom’s drug shows sustained benefit at 2 yearsIbrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, a rare form of lymphoma, continued to control the rare blood cancer, with 95% of patients surviving for 2 years, according to a new study, published in The New England Journal of Medicine.